Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454622 | 1.00 | EBP (0.70) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL14146050 | 1.00 | EBP (0.70) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL11927700 | 1.00 | EBP (0.70) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL11927701 | 1.00 | EBP (0.70) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| Hydrochloric Acid SCHEMBL28017968 | 0.98 | EBP (0.68) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| Hydrochloric Acid SCHEMBL28469297 | 0.98 | EBP (0.68) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL11461237 | 0.94 | EBP (0.67) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL11461196 | 0.91 | EBP (0.67) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL11462886 | 0.88 | SIGMAR1 (0.74) | EBPSIGMAR1ADORA3CHRM1DRD3 | |
| SCHEMBL9363925 | 0.87 | SIGMAR1 (0.77) | EBPSIGMAR1ADORA3CHRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097398-B1 | PROCESS OF PRODUCING AMOROLFINE FREE BASE | GALDERMA SA (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2398570-B1 | PROCESS FOR THE PURIFICATION OF AMOROLFINE HYDROCHLORIDE | SYNTECO S P A PRODOTTI DI SINTESI PER L IND CHIMICA E FARMACEUTICA (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8664381-B2 | Process for the preparation and purification of amorolfine hydrochloride | SYNTECO S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| US-8664381-B2 | Process for the preparation and purification of amorolfine hydrochloride | SYNTECO S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| EP-1912961-B1 | PROCESS OF PRODUCING BEPROMOLINE | GALDERMA SA (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-8242268-B2 | Production of bepromoline | GALDERMA S.A. (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242268-B2 | Production of bepromoline | GALDERMA S.A. (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110301346-A1 | PROCESS FOR THE PURIFICATION OF AMOROLFINE HYDROCHLORIDE | SYNTECO S.P.A.-PRODOTTI DI SINTESI PER L'INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 2011-12-08 | — | — | US | disclosed |
| US-20110301346-A1 | PROCESS FOR THE PURIFICATION OF AMOROLFINE HYDROCHLORIDE | SYNTECO S.P.A.-PRODOTTI DI SINTESI PER L'INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 2011-12-08 | — | — | US | disclosed |
| US-8049007-B2 | Preparation of amorolfine | GALDERMA S.A. (CH) | 2011-11-01 | — | — | US | disclosed |
| EP-1749825-A1 | Process of producing amorolfine | Galderma S.A. (CH) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749826-A1 | Process of producing bepromoline | Galderma S.A. (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2007012984-A2 | PROCESS OF PRODUCING BEPROMOLINE | GALDERMA S.A. (CH) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012983-A2 | PROCESS OF PRODUCING AMOROLFINE | GALDERMA S.A. (CH) | 2007-02-01 | — | — | WO | disclosed |
| US-4785100-A | BROMINATION FOLLOWED BY AMINATION | HUELS AKTIENGESELLSHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0024334-B1 | MORPHOLINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-07-20 | — | — | EP | disclosed |
| EP-0017893-B1 | PROCESS FOR THE PREPARATION OF HETEROCYCLIC TERTIARY ARALKYL AMINES | BASF Aktiengesellschaft (DE) | 1982-03-24 | — | — | EP | disclosed |
| US-4283534-A | Reductive alkylation of nitrogen heterocycles | BASF AKTIENGESELLSCHAFT (DE) | 1981-08-11 | — | — | US | disclosed |
| EP-0024334-A1 | Morpholine derivatives, process for their production, pharmaceutical preparations containing these derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-03-04 | — | — | EP | disclosed |
| EP-0017893-A1 | Process for the preparation of heterocyclic tertiary aralkyl amines | BASF Aktiengesellschaft (DE) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301346-A1 | PROCESS FOR THE PURIFICATION OF AMOROLFINE HYDROCHLORIDE | PAH, PREP, IMPDH1 | EBP 3172/4885SIGMAR1 708/4885ADORA3 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.